Clinical trial NCT02737332: A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer
Official title: A Randomized, Open-Label, Active-Controlled, Multi-Center Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer: The STAAR STUDY
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Prostate Cancer
Lead sponsor: Sun Pharmaceutical Industries Limited
Sponsor class: INDUSTRY
First posted: 2016-04-13
Enrollment: 53
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the serum testosterone levels in patients with Metastatic Castration-Resistant Prostate Cancer on SoluMatrix™ Abiraterone Acetate as Compared to Abiraterone Acetate

Detailed description: This was a 12-week, open-label study of abiraterone acetate in at least 50 patients with metastatic castration-resistant prostate cancer.

Eligibility criteria: Inclusion Criteria:

1. Written informed consent obtained prior to any study-related procedure being performed
2. Male subjects at least 18 years of age or older at time of consent
3. Pathologically confirmed adenocarcinoma of the prostate
4. Ongoing therapy with a GnRH agonist or antagonist AND serum testosterone level \<50 ng/dL at screening
5. Metastatic disease documented by computed tomography (CT)/ magnetic resonance imaging (MRI) or bone scan. Imaging obtained within 42 days prior to the start of study medication will be accepted.
6. Meeting disease progression according to the recommendations of the prostate cancer working group 2 by one of the following criteria:

   * Two rises of PSA (taken a minimum of 1 week apart) from a baseline measurement of at least 2 ng/mL,
   * Imaging progression (CT/MRI) by RECIST criteria
   * Nuclear scan progression by new lesion.
7. Discontinuation of flutamide or nilutamide, and other anti-androgens at least 4 weeks prior to the start of study medication; discontinuation of bicalutamide at least 6 weeks prior to start of study medication.
8. Discontinuation of Radiotherapy \> 4 weeks prior to start of study medication.
9. ECOG performance status of 0-1 at screening
10. Screening blood counts of the following:

    * Absolute neutrophil count \> 1500/µL
    * Platelets \> 100,000/µL
    * Hemoglobin \> 9 g/dL
11. Screening chemistry values of the following:

    * ALT and AST \< 2.5 x ULN
    * Total bilirubin \< 1.5 x ULN
    * Creatinine\< 1.5 x ULN
    * Albumin \> 3.0 g/dL
12. Potassium \> 3.5 mmol/L
13. Life expectancy of at least 6 months at screening
14. Subject is willing and able to comply with all protocol requirements assessments
15. Agrees to protocol-defined use of effective contraception.

Exclusion Criteria:

1. History of impaired pituitary or adrenal gland function
2. Prior therapy with abiraterone acetate, orteronel, ketoconazole or any other CYP17 inhibitor
3. Prior therapy with enzalutamide
4. Prior use of experimental androgen receptor antagonist
5. Previous exposure to Ra-223:Xofigo
6. Previous chemotherapy
7. Initiation of bisphosphonate or denosumab therapy within 30 days prior to the start of study medication. Patients who are on a stable dose of these medications for at least 30 days at the time of starting study drug are eligible.
8. Therapy with estrogen within 30 days prior to the start of study medication
9. Use of systemic glucocorticoids equivalent to \> 10 mg of prednisone daily; patients who have discontinued or have reduced dose to \< 10 mg prednisone within 14 days prior to the start of study medication will be eligible
10. Prior use of any herbal products that may decrease PSA levels (eg., saw palmetto) within 30 days of start of study medication
11. Known metastases to the brain or CNS involvement
12. History of other malignancy within the previous 2 years
13. Major surgery within 30 days prior to the start of study medication
14. Blood transfusion within 30 days of screening
15. Serious, persistent infection within 14 days of the start of study medication
16. Persistent pain that requires the use of a narcotic analgesic
17. Known gastrointestinal disease or condition that may impair absorption
18. Treatment with any investigational drug within 4 weeks prior to Day -1 of the study.
19. Known history of human immunodeficiency virus (HIV) or seropositive test for hepatitis C virus or hepatitis B virus
20. Have poorly controlled diabetes.
21. Uncontrolled hypertension
22. History of New York Heart Association (NYHA) class III or IV heart failure
23. Serious concurrent illness, including psychiatric illness, that would interfere with study participation
24. Inability to swallow tablets whole
25. Known hypersensitivity to any excipients in study medications
26. Moderate to severe hepatic impairment (Child-Pugh Classes B and C)

Primary outcomes:
measure: Testosterone Levels
timeFrame: Average of Day 9 and 10
Secondary outcomes:
measure: PSA Levels
timeFrame: Day 28, Day 56, and Day 84
measure: Percent of Subjects With PSA-50 Response
timeFrame: Day 28, Day 56, and Day 84
measure: Serum Testosterone Levels
timeFrame: Day 28, Day 56, and Day 84
measure: Steady State Trough Concentration of Arbiraterone
timeFrame: Day 09, Day 28, Day 56, and Day 84
measure: AUC (0-inf)
timeFrame: 60 to 30 minutes prior to dosing and over 24 Hours post-dose
measure: AUC (0-24 hr)
timeFrame: 60 to 30 minutes prior to dosing and over 24 Hours post-dose
measure: AUC (0-t)
timeFrame: 60 to 30 minutes prior to dosing and over 24 Hours post-dose
measure: Cmax
timeFrame: 60 to 30 minutes prior to dosing and over 24 Hours post-dose
Other outcomes:
Locations:
city: Laguna Hills
country: United States
facility: Alliance Research
state: California
city: Los Angeles
country: United States
facility: Tower Urology
state: California
city: San Bernardino
country: United States
facility: San Bernardino Urological
state: California
city: Torrance
country: United States
facility: Skyline Urology
state: California
city: Whittier
country: United States
facility: Innovative Clinical Research Institute
state: California
city: Englewood
country: United States
facility: Urology Associates, P.C.
state: Colorado
city: Bradenton
country: United States
facility: Manatee Medical Research
state: Florida
city: Coeur d'Alene
country: United States
facility: North Idaho Urology
state: Idaho
city: West Des Moines
country: United States
facility: The Iowa Clinic
state: Iowa
city: Wichita
country: United States
facility: Wichita Urology Group
state: Kansas
city: Towson
country: United States
facility: Chesapeake Urology Research Associates
state: Maryland
city: Lincoln
country: United States
facility: Lincoln Urology, PC
state: Nebraska
city: Omaha
country: United States
facility: Urology Cancer Center
state: Nebraska
city: Brooklyn
country: United States
facility: Brooklyn Urology Research Group
state: New York
city: Raleigh
country: United States
facility: Associated Urologist of North Carolina
state: North Carolina
city: Dallas
country: United States
facility: Urology Clinics of North Texas
state: Texas
city: Virginia Beach
country: United States
facility: Urology of Virginia
state: Virginia
Study officials:
name: Paul Nemeth, PhD
role: STUDY_DIRECTOR
References: